Table 1.

Characteristics of 61 included early-stage breast cancer patients and their tumors, treated with NAC and surgery in 4 Dutch hospitals.

		Total (N = 61)
Age (years)	Median (Min, Max)	50.0 (25, 72)
Histology	Invasive carcinoma NST	53 (86.9%)
	Ductolobular carcinoma	2 (3.3%)
	Lobular carcinoma	5 (8.2%)
	Mucinous carcinoma	1 (1.6%)
Grade	2	24 (39.3%)
	3	37 (60.7%)
Receptor subtype	ER−/HER2−	21 (34.4%)
	ER + −/HER2+	17 (27.9%)
	ER + /HER2−	23 (37.7%)
cT stage	T1	11 (18.3%)
	T2	37 (61.7%)
	T3	12 (20.0%)
	Missing	1
Nodal metastases	Absent	23 (37.7%)
	Present	38 (62.3%)
Neoadjuvant treatment	Paclitaxel, trastuzumab, carboplatin and pertuzumab	16 (26.2%)
	Doxorubicin and paclitaxel	26 (42.6)
	Doxorubicin, paclitaxel and carboplatin	18 (29.5%)
	Paclitaxel and trastuzumab	1 (1.6%)
Radiologist conclusion MRI on-treatment	Partial response	47 (77.0%)
	Radiological complete remission	9 (14.8%)
	No response	4 (6.6%)
	Missing	1 (1.6%)
Radiologist conclusion MRI post-treatment NAC	Partial response	21 (34.4%)
	Radiological complete remission	36 (59.0%)
	No response	2 (3.3%)
	Missing	2 (3.3%)
Surgery type	Mastectomy	36 (59.0%)
	Lumpectomy	25 (41.0%)
Pathological complete response	Yes No	23 (38%) 38 (62%)
Residual Cancer Burden	Median (Min, Max)	1.254 (0, 3.42)

ER estrogen receptor, HER2 Human epidermal growth factor receptor-2.